Nuclear Medicine Market is estimated to be valued at USD 18.32 Bn in 2025 and is expected to reach USD 38.52 Bn by 2032, growing at a compound annual growth rate (CAGR) of 11.2% from 2025 to 2032.
Report Coverage |
Report Details |
Base Year: |
2024 |
Market Size in 2025: |
USD 18.32 Bn |
Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: |
11.20% |
2032 Value Projection: |
USD 38.52 Bn |
The global nuclear medicine market has witnessed significant growth in recent years, driven by the increasing prevalence of chronic diseases, advancements in nuclear medicine technology, and the growing demand for personalized medicine. Nuclear medicine involves the use of radioactive substances for diagnostic and therapeutic purposes, enabling the early detection and treatment of various diseases, including cancer, cardiovascular disorders, and neurological conditions. The market encompasses a wide range of products and services, such as radiopharmaceuticals, imaging equipment, and software solutions, catering to the diverse needs of healthcare professionals and patients worldwide. As the healthcare industry continues to evolve and embrace innovative technologies, the nuclear medicine market is poised for further expansion and development in the coming years.
Market Dynamic
The global nuclear medicine market is influenced by several key drivers, restraints, and opportunities. One of the primary drivers is the rising incidence of chronic diseases, such as cancer and cardiovascular disorders, which require advanced diagnostic and therapeutic interventions. Additionally, the growing geriatric population worldwide is expected to fuel the demand for nuclear medicine procedures, as older individuals are more susceptible to age-related diseases. Technological advancements, including the development of hybrid imaging modalities and the introduction of novel radiopharmaceuticals, are also driving market growth by improving the accuracy and efficiency of nuclear medicine procedures. However, the market faces certain restraints, such as the high cost of nuclear medicine equipment and the stringent regulatory requirements for the approval and use of radiopharmaceuticals. The shortage of skilled professionals trained in nuclear medicine techniques also poses a challenge to market growth. Despite these restraints, the nuclear medicine market presents significant opportunities for growth, particularly in emerging economies, where there is a rising demand for advanced healthcare services. The increasing adoption of nuclear medicine in the diagnosis and treatment of neurological disorders, such as Alzheimer's and Parkinson's disease, is another promising opportunity for market expansion.
Key Features of the Study
- This report provides in-depth analysis of the global nuclear medicine market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global nuclear medicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Siemens Healthineers, GE Healthcare, Philips Healthcare, Toshiba Medical Systems, Bracco Imaging, Canon Medical Systems, EczacIbasI-Monrol, Mallinckrodt Pharmaceuticals, Lantheus Medical Imaging, Bayer AG, RadioMedix, IBA Radiopharma Solutions, Nordion (a Sotera Health company), Advanced Accelerator Applications, and Actinium Pharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global nuclear medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nuclear medicine market
Market Segmentation
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Diagnostic Nuclear Medicine
- SPECT Radiopharmaceuticals
- Tc-99m
- I-123
- Tl-201
- Ga-67
- Other SPECT Isotopes
- PET Radiopharmaceuticals
- F-18
- Rb-82
- Other PET Isotopes
- Therapeutic Nuclear Medicine
- Alpha Emitters
- Ra-223
- Beta Emitters
- I-131
- Y-90
- Sm-153
- Lu-177
- Re-186
- Other Beta Emitters
- Brachytherapy Isotopes
- Cesium-131
- Iodine-125
- Palladium-103
- Iridium-192
- Others
- Application Insights (Revenue, USD Bn, 2020 - 2032)
- Oncology
- Cardiology
- Neurology
- Endocrinology
- Bone Metastasis
- Gastroenterology
- Pulmonology
- Infectious Diseases
- Others
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals & Clinics
- Diagnostic Centers
- Research Laboratories
- Academic Institutions
- Others
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Siemens Healthineers
- GE Healthcare
- Philips Healthcare
- Toshiba Medical Systems
- Bracco Imaging
- Canon Medical Systems
- EczacIbasI-Monrol
- Mallinckrodt Pharmaceuticals
- Lantheus Medical Imaging
- Bayer AG
- RadioMedix
- IBA Radiopharma Solutions
- Nordion (a Sotera Health company)
- Advanced Accelerator Applications
- Actinium Pharmaceuticals